<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://gate.unigre.it/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=ScottMoor642440</id>
	<title>GATE - User contributions [en]</title>
	<link rel="self" type="application/atom+xml" href="https://gate.unigre.it/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=ScottMoor642440"/>
	<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php/Special:Contributions/ScottMoor642440"/>
	<updated>2026-05-30T13:26:26Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.35.7</generator>
	<entry>
		<id>https://gate.unigre.it/mediawiki/index.php?title=Monitoring_Metabolism_Of_Synthetic_Cannabinoid_4F-MDMB-BINACA_Via_High-resolution_Mass_Spectrometry_Assessed_In_Cultured_Hepatoma_Cell_Line,_Fungus,_Liver_Microsomes_And_Confirmed_Using_Urine_Samples_Forensic_Toxicology_Springer_Nature_Link&amp;diff=149042</id>
		<title>Monitoring Metabolism Of Synthetic Cannabinoid 4F-MDMB-BINACA Via High-resolution Mass Spectrometry Assessed In Cultured Hepatoma Cell Line, Fungus, Liver Microsomes And Confirmed Using Urine Samples Forensic Toxicology Springer Nature Link</title>
		<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php?title=Monitoring_Metabolism_Of_Synthetic_Cannabinoid_4F-MDMB-BINACA_Via_High-resolution_Mass_Spectrometry_Assessed_In_Cultured_Hepatoma_Cell_Line,_Fungus,_Liver_Microsomes_And_Confirmed_Using_Urine_Samples_Forensic_Toxicology_Springer_Nature_Link&amp;diff=149042"/>
		<updated>2026-05-28T19:24:16Z</updated>

		<summary type="html">&lt;p&gt;ScottMoor642440: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Moreover, genetic makeup, physiological conditions (age, gender and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drug&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to https://cannabinoidsrc4f-adb.com/ reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.&amp;lt;br&amp;gt;The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in human users. The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids, drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Figure 1. &amp;lt;br&amp;gt;These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Acute kidney damage and even kidney failure have been reported following use of synthetic cannabinoids (Davidson, et al., 2017). One recent study has looked at other mechanisms of action in some of the older synthetic cannabinoids and reported that some produced varying amounts of activity at sites which are related to cardiotoxicity and heart disease (Wiley et al., 2016). It is not known whether the increased toxicity is due only to activation of CB1 cannabinoid receptors more strongly than Δ9-THC or whether these &amp;quot;super-strength&amp;quot; cannabinoids produce effects at other receptors. A major cause of concern is that some of the more recently seen synthetic cannabinoids are more likely to produce extremely toxic effects than the older synthetics (Tai and Fantegrossi, 2017&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those [https://cannabinoidsrc4f-adb.com/ https://cannabinoidsrc4f-adb.com/] of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018). The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk in human recreational users.&amp;lt;br&amp;gt;Michael B Gatch &amp;lt;br&amp;gt;Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose of Δ9-TH&lt;/div&gt;</summary>
		<author><name>ScottMoor642440</name></author>
	</entry>
	<entry>
		<id>https://gate.unigre.it/mediawiki/index.php?title=JWH-210_CHEMICAL_POWDER&amp;diff=148492</id>
		<title>JWH-210 CHEMICAL POWDER</title>
		<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php?title=JWH-210_CHEMICAL_POWDER&amp;diff=148492"/>
		<updated>2026-05-25T07:12:16Z</updated>

		<summary type="html">&lt;p&gt;ScottMoor642440: Created page with &amp;quot;In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitmen...&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to 4F ADB quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.&amp;lt;br&amp;gt;Key Features and Specifications to Evaluate &amp;lt;br&amp;gt;Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research or analysis. For legitimate applications, only fully characterized, independently tested JWH-210 [https://cannabinoidsrc4f-adb.com/ 4F ADB] should be considered.&amp;lt;br&amp;gt;How to Choose Powder JWH-210 &amp;lt;br&amp;gt;When learning how to choose powder JWH-210, the most critical factor is verifying high chemical purity (≥98%) from a reputable supplier with independent lab testing. We also demonstrated that JWH-210 administration resulted in the decrease of expression levels of T-cell activator including Cd3e, Cd3g, Cd74p31, and Cd74p41, while JWH-030 increased Cd3g levels. JWH-210 (10 mg/kg, 3 days, i.p.) is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH-030 of ICR mice in vivo. Users are expected to handle the compound in accordance with all applicable regulations and safety guidelines within their jurisdiction. It is important to note that JWH-210 Chemical Powder is intended strictly for research and laboratory use only. Its reputation for purity and stability has contributed to its widespread use in controlled environments where precision is paramount.&amp;lt;br&amp;gt;Is JWH-210 Legal? &amp;lt;br&amp;gt;To evaluate whether the changes of coordinative functions by CNS damages were due to test substances, rota-rod test was performed using Rota-rod apparatus (Daejong, Seoul, Korea). The test apparatus for the locomotor activity test was designed to measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in the chamber. In both tests, a group of mice were treated with negative control (vehicle, 1 mg/kg, i.p.), positive control (methamphetamine, 1 mg/kg, i.p.), or one of the three doses of test substances (0.1, 1, 5 mg/kg, i.p.) once every other day for 10 day&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patien&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug law&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Similarly, precursor ion identified at m/z 380 (B19/B21, B23/B25) was 16 Da higher than the 4F-MDMB-BINACA, indicating monohydroxylation at the butyl side chain (B19/B21) and indazole (B23/B25) moieties with product ions m/z 145 and 161, respectively. Metabolites identified at m/z 366 (B8, B9, B13), which was 16 Da higher than the 4F-MDMB-BINACA ester hydrolysis metabolite (B22), confirmed monohydroxylation upon ester hydrolysis. Death involving these drugs have been reported [5,6,7,8,9], and this raises public health and social concerns. Due to their similar physiological effects to the principal psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), SCBs are gaining popularity and are often abused as recreational drugs. The fact that similar 4F-MDMB-BINACA and ethanol concentrations were detected in the postmortem blood samples of both victims suggests that both substances played a role in the fatal outcom&lt;/div&gt;</summary>
		<author><name>ScottMoor642440</name></author>
	</entry>
</feed>